What is the share price of SMS Pharmaceuticals Ltd (SMSPHARMA) today?
The share price of SMSPHARMA as on 7th August 2026 is ₹378.10. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The past returns of SMS Pharmaceuticals Ltd (SMSPHARMA) share are- Past 1 week: -9.72%
- Past 1 month: -15.53%
- Past 3 months: -13.72%
- Past 6 months: 12.33%
- Past 1 year: 66.36%
- Past 3 years: 197.54%
- Past 5 years: 85.13%
What are the peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA)?
The peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA) include:What is the dividend yield % of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The current dividend yield of SMS Pharmaceuticals Ltd (SMSPHARMA) is 0.11.What is the market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹3345.25 Cr as of 7th August 2026.What is the 52 week high and low of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The 52-week high of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹447.80 and the 52-week low is ₹207.99.What is the PE and PB ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) stock?
The P/E (price-to-earnings) ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) is 32.80. The P/B (price-to-book) ratio is 5.23.Which sector does SMS Pharmaceuticals Ltd (SMSPHARMA) belong to?
SMS Pharmaceuticals Ltd (SMSPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares?
You can directly buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SMS Pharmaceuticals Ltd
SMSPHARMA Share Price
NSE₹378.105.85% (+20.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SMSPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SMSPHARMA Performance & Key Metrics
SMSPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 32.67 | 5.23 | 0.11% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.50 | 6.02 | 0.50% |
SMSPHARMA Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SMSPHARMA Company Profile
SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.
SUNPHARMA
PE Ratio
40.78
40.78
1Y Return
22.30%
22.30%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
87.14
87.14
1Y Return
40.63%
40.63%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.76
30.76
1Y Return
0.65%
0.65%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
21.93
21.93
1Y Return
18.79%
18.79%
Buy Reco %
53.57
53.57
LUPIN
PE Ratio
20.45
20.45
1Y Return
28.79%
28.79%
Buy Reco %
54.29
54.29
SMSPHARMA Sentiment Analysis
SMSPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SMSPHARMA Stock Summary · May 2026
Management characterized FY26 as a year of solid growth and margin expansion underpinned by strategic integration and capacity investment; full-year revenue rose 13% to INR 887 crore and EBITDA margin improved to 20%. Management emphasized a pragmatic, execution‑focused tone, citing backward integration—notably in ibuprofen and in‑house intermediates—as the primary driver of margin resilience and reduced supply‑chain exposure, while directing capital toward a brownfield expansion and dedicated capacity for higher‑value APIs and recently filed DMFs. They also highlighted a meaningful associate contribution that materially supported reported profit and is expected to strengthen into FY27. Management acknowledged tensions from Middle East geopolitical disruption and a March spike in solvent costs that dented gross margin, and described a portfolio shift toward ARVs and anti‑inflammatory products even as peptide and CDMO initiatives are being advanced for medium‑term upside. For FY27 they guided to roughly 15% revenue growth and reiterated a target to lift EBITDA margin toward 22%, with medium‑term organic growth targets of 20–25% for FY28–29.
SMSPHARMA Stock Growth Drivers
SMSPHARMA Stock Growth Drivers
6Robust FY26 financial performance and margin expansion
The company delivered solid FY26 results with full-year revenue rising 13% to INR887 crore and
Backward integration driving resilience and margin upside
The company’s multi-year backward integration program—notably for ibuprofen and other intermediates—has moved production in‑house over
SMSPHARMA Stock Challenges
SMSPHARMA Stock Challenges
4Geopolitical-driven supply-chain and logistics disruption prompting a cautious outlook
Management has adopted a prudent FY27 stance because ongoing geopolitical developments in the Middle East
Raw‑material cost shock and resulting margin erosion
The company reported an approximately 2 percentage‑point quarter‑on‑quarter decline in gross margin attributable primarily to
SMSPHARMA Forecast
SMSPHARMA Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SMSPHARMA
SMSPHARMA
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SMSPHARMA Income Statement
SMSPHARMA Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 247.44 | 165.82 | 198.05 | 175.48 | 249.62 | 196.64 | 243.86 | 214.20 | 240.52 | 208.71 | ||||||||||
Operating & Other expenses | 212.18 | 130.94 | 165.28 | 140.14 | 207.39 | 156.68 | 194.06 | 166.80 | 198.05 | 166.01 | ||||||||||
EBITDA | 35.26 | 34.88 | 32.77 | 35.34 | 42.23 | 39.96 | 49.80 | 47.40 | 42.47 | 42.70 | ||||||||||
| Depreciation/Amortization | 7.92 | 8.38 | 8.62 | 8.70 | 8.64 | 9.75 | 10.02 | 10.02 | 10.13 | 9.99 | ||||||||||
| PBIT | 27.34 | 26.50 | 24.15 | 26.64 | 33.59 | 30.21 | 39.78 | 37.38 | 32.34 | 32.71 | ||||||||||
| Interest & Other Items | 5.61 | 4.67 | 4.61 | 4.20 | 5.07 | 5.84 | 5.74 | 6.22 | 5.28 | 5.50 | ||||||||||
| PBT | 21.73 | 21.83 | 19.54 | 22.44 | 28.52 | 24.37 | 34.04 | 31.16 | 27.06 | 27.21 | ||||||||||
| Taxes & Other Items | 4.46 | 5.36 | 5.44 | 4.20 | 8.21 | 3.87 | 8.73 | 7.69 | -5.65 | 6.29 | ||||||||||
| Net Income | 17.27 | 16.47 | 14.10 | 18.24 | 20.31 | 20.50 | 25.31 | 23.47 | 32.71 | 20.92 | ||||||||||
| EPS | 2.04 | 1.95 | 1.67 | 2.15 | 2.40 | 2.31 | 2.84 | 2.59 | 3.58 | 2.23 |
SMSPHARMA Company Updates
FY 2027FY 2027
Investor Presentation
Aug 1PDF
FY 2026FY 2026
Investor Presentation
Feb 9PDF
Nov 10PDF
Aug 10PDF
SMSPHARMA Stock Peers
SMSPHARMA Past Performance & Peer Comparison
SMSPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SMS Pharmaceuticals Ltd | 32.80 | 5.23 | 0.11% |
| Sun Pharmaceutical Industries Ltd | 40.78 | 5.58 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.14 | 10.72 | 0.68% |
| Cipla Ltd | 30.76 | 3.46 | 0.88% |
SMSPHARMA Stock Price Comparison
Compare SMSPHARMA with any stock or ETFCompare SMSPHARMA with any stock or ETF
SMSPHARMA
SMSPHARMA Holdings
SMSPHARMA Shareholdings
SMSPHARMA Promoter Holdings Trend
SMSPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SMSPHARMA Institutional Holdings Trend
SMSPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding History
SMSPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in SMSPHARMA
Mutual Funds Invested in SMSPHARMA
No mutual funds holding trends are available
Top 3 Mutual Funds holding SMS Pharmaceuticals Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.2934% | Percentage of the fund’s portfolio invested in the stock 0.23% | Change in the portfolio weight of the stock over the last 3 months -0.04% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 85/133 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.9530% | Percentage of the fund’s portfolio invested in the stock 8.15% | Change in the portfolio weight of the stock over the last 3 months -2.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/41 (-10) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 90/130 (-11) |
Compare 3-month MF holding change on Screener
smallcases containing SMSPHARMA stock
smallcases containing SMSPHARMA stock
Looks like this stock is not in any smallcase yet.
SMSPHARMA Events
SMSPHARMA Events
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.06 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.11%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.06 every year
SMSPHARMA Upcoming Dividends
SMSPHARMA Upcoming Dividends
No upcoming dividends are available
SMSPHARMA Past Dividends
SMSPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2021
SMSPHARMA Stock News & Opinions
SMSPHARMA Stock News & Opinions
Articles & Videos
Corporate
Corporate
SMS Pharmaceuticals reports Rs 207 crore revenue, 6% growth, and approves Rs 50 crore loanSMS Pharmaceuticals Limited (NSE: SMSPHARMA; BSE:532815) announced its unaudited financial results for the quarter ended June 30, 2026, reporting revenue from operations of Rs 207.0 crore, a 6% year-over-year increase driven by broad-based growth across high-value APIs. The company’s profit after tax increased 8% year-over-year to Rs 20.20 crore, while maintaining an EBITDA margin of 20%, and the board approved an infusion of up to Rs 50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to establish a dedicated peptide R&D facility.
5 days agoCapital Market - Live
Earnings
Earnings
SMS Pharmaceuticals Ltd consolidated sales down 13.02% on year in Q2FY2026, net profit softened by 3.63%SMS Pharmaceuticals Ltd share price declined 5.65% to Rs 373.75 after the company's net profit slipped by 3.63% to Rs 20.2 crore, while revenue from operations reduced 13.02% to Rs 206.96 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, rising 6%. It has improved by 2.79% over last one week and rallied by 15.59% in last one month while the market capitalization of SMS Pharmaceuticals Ltd has eased by 1.73% and 7.50% in the same period respectively. Profit before tax (PBT) of SMS Pharmaceuticals Ltd stood at Rs 27.21 crore in Q2 FY26, rising by 11.65% year-on-year, and gaining 0.52% quarter-on-quarter. EBITDA came in at Rs 39 crore, easing 1.11% YoY and gaining 5.04% sequentially. Total expenses reduced by 15.46% to Rs 176.0 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 136.65 crore, posting a minor increase of 6.38% YoY, while employee benefits expense was at Rs 23.54 crore, tumbling by 20.12% YoY. For the TTM ended FY26, revenue from operations rose 10.36% to Rs 782.75 crore, while net profit jumped 36.99% to Rs 67.4 crore, compared to previous TTM. EBITDA surged by 11398% to Rs 132.77 crore, and PBT witnessed a strong rise of 39.68% to Rs 92.34 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 81.71 crore in FY26, as against Rs 50.12 crore in FY25. SMS Pharmaceuticals Ltd rallied 57.57% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 4.36% during the same period.
6 days agoCapital Market - Live
Corporate
Corporate
SMS Pharmaceuticals reschedules board meeting to review quarterly financial resultsSMS Pharmaceuticals Limited informed the BSE Limited and National Stock Exchange of India Ltd. that the Board of Directors meeting, previously scheduled for August 1, 2026, has been rescheduled to July 31, 2026, to consider and approve the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026. The company also stated that the trading window for its equity shares will be closed from July 1, 2026, to August 2, 2026, and will reopen on August 3, 2026, in accordance with SEBI regulations.
1 week agoCapital Market - Live
Corporate
Corporate
SMS Pharmaceuticals to announce Quarterly ResultSMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1 August 2026.
1 week agoCapital Market - Live
Corporate
Corporate
Board of SMS Pharmaceuticals recommends final dividendSMS Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 0.4 per equity Share (i.e. 40%) , subject to the approval of the shareholders.
2 months agoCapital Market - Live
Earnings
Earnings
SMS Pharmaceuticals consolidated net profit rises 60.97% in the March 2026 quarterNet profit of SMS Pharmaceuticals rose 60.97% to Rs 32.71 crore in the quarter ended March 2026 as against Rs 20.32 crore during the previous quarter ended March 2025. Sales declined 4.13% to Rs 237.95 crore in the quarter ended March 2026 as against Rs 248.20 crore during the previous quarter ended March 2025. For the full year,net profit rose 47.51% to Rs 101.99 crore in the year ended March 2026 as against Rs 69.14 crore during the previous year ended March 2025. Sales rose 13.30% to Rs 886.87 crore in the year ended March 2026 as against Rs 782.75 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales237.95248.20 -4 886.87782.75 13 OPM %16.7716.44 -19.3117.76 - PBDT37.2037.16 0 156.56126.67 24 PBT27.0728.52 -5 116.6492.34 26 NP32.7120.32 61 101.9969.14 48 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
SMS Pharmaceuticals announces board meeting dateSMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2026.
2 months agoCapital Market - Live
Spotlight
Spotlight
SMS Pharma edges higher after Q3 PAT rises nearly 29% YoYTotal operating expenses for the period under review aggregated to Rs 166.80 crore, up 19.0% YoY. PBIDT improved by 34.1% to Rs 47.40 crore in Q3 FY26 from Rs 35.34 crore in Q3 FY25. Profit before tax in Q3 FY26 stood at Rs 31.16 crore, up by 38.9% from Rs 22.44 crore recorded in Q3 FY25. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag. Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Earnings
SMS Pharmaceuticals consolidated net profit rises 28.67% in the December 2025 quarterNet profit of SMS Pharmaceuticals rose 28.67% to Rs 23.47 crore in the quarter ended December 2025 as against Rs 18.24 crore during the previous quarter ended December 2024. Sales rose 21.40% to Rs 210.45 crore in the quarter ended December 2025 as against Rs 173.35 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales210.45173.35 21 OPM %20.7419.16 - PBDT41.1831.13 32 PBT31.1622.44 39 NP23.4718.24 29 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
SMS Pharmaceuticals to announce Quarterly ResultSMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 February 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.58%, vs industry avg of 12.48%
Over the last 5 years, market share decreased from 0.2% to 0.17%
Over the last 5 years, net income has grown at a yearly rate of 10.28%, vs industry avg of 10.55%